Luspatercept Shows Survival Advantage Over ESA in Low-Risk MDS After Three Years
Key Insights
Luspatercept doubled transfusion independence rates compared to erythropoietin-stimulating agents in the phase 3 COMMANDS trial, achieving 60% versus 35% response rates in low-risk myelodysplastic syndromes (search).
The survival benefit emerged after three years of treatment, with luspatercept showing superior overall survival compared to ESA (search) in a piecewise analysis at 36 months or longer.
Duration of transfusion independence was significantly longer with luspatercept, particularly benefiting patients with SF3B1 (search) mutations who achieved 70% response rates versus 33% with ESA (search).
Luspatercept (Reblozyl) has demonstrated a significant survival advantage over erythropoietin-stimulating agents (ESA (search)) in patients with low-risk myelodysplastic syndromes (search) (MDS (search)), marking the first therapy to show improved overall survival in this patient population. The findings from the phase 3 COMMANDS trial reveal that the survival benefit emerges after three years of treatment, with patients receiving luspatercept showing superior outcomes compared to those on ESA therapy.
Doubled Response Rates in Transfusion Independence
The COMMANDS trial (NCT03682536) evaluated luspatercept versus epoetin alfa in patients with transfusion-dependent, low-risk MDS (search) who had serum erythropoietin levels below 500 U/L. The study enrolled patients requiring at least two transfusions within eight weeks, regardless of ring sideroblast status or SF3B1 (search) mutation presence.
Patients treated with luspatercept achieved remarkable improvements in transfusion independence, with response rates doubling from 35% with ESA (search) to 60% with luspatercept (P < .0001). The benefit was particularly pronounced in patients with SF3B1 (search) mutations, who comprised approximately 63% of each treatment arm. In this subgroup, luspatercept achieved a 70% response rate compared to 33% with ESA.
For patients without SF3B1 (search) mutations, representing about half of all low-risk MDS (search) patients, the difference was not statistically significant, with response rates of 45% versus 36% for luspatercept and ESA (search), respectively. Similarly, in patients without ring sideroblasts, both treatments showed comparable efficacy at 47% versus 50%.
Sustained Duration of Response Drives Survival Benefit
Long-term follow-up data presented at the 2024 American Society of Hematology (search) Annual Meeting demonstrated that luspatercept's superiority persists over time. Patients maintained transfusion independence for significantly longer durations, with benefits extending to one-year and 1.5-year transfusion independence milestones.
The most striking finding emerged from overall survival data presented at the 2025 American Society of Clinical Oncology meeting. For the first three years, patients receiving ESA (search) and luspatercept showed similar survival rates. However, after three years, a clear separation occurred, with luspatercept-treated patients demonstrating superior overall survival in a piecewise analysis at 36 months or longer (HR, 0.330; 95% CI, 0.128-0.853; P = .0221).
Mechanism Behind Survival Advantage
The survival benefit appears to stem from luspatercept's ability to provide longer-lasting transfusion independence rather than disease modification. According to trial investigators, the extended duration of response likely reduces cardiovascular mortality in this elderly patient population by maintaining higher hemoglobin levels for longer periods, thereby decreasing the risk of heart attacks and strokes associated with chronic anemia (search).
Luspatercept works by allowing maturation of red blood cells rather than modifying the underlying disease course. The sustained transfusion independence translates to improved time to first red blood cell transfusion, with patients experiencing longer intervals before requiring transfusion support.
Safety Profile and Clinical Considerations
The safety profile of luspatercept showed manageable adverse events, with fatigue being the most notable concern. Any-grade fatigue occurred in approximately 20% of patients in the luspatercept arm compared to 8% with ESA (search). Patients typically experience fatigue for one to two days following treatment, with recovery by the third day.
Based on these findings, luspatercept may be preferred even in patients without favorable prognostic factors such as ring sideroblasts or SF3B1 (search) mutations, particularly those with EPO levels below 200 U/L. While response rates may be similar between treatments in these subgroups, the longer duration of response with luspatercept could provide meaningful clinical benefits and potential survival advantages.
The COMMANDS trial represents a significant advancement in low-risk MDS (search) treatment, establishing luspatercept as the first therapy to demonstrate improved overall survival in this patient population through sustained management of anemia (search) and transfusion dependence.